(19) World Intellectual Property Organization International Bureau



1 (1814) 1 (1814) (1 (1814) 1 (1814)

(43) International Publication Date 10 March 2005 (10.03.2005)

PCT

(10) International Publication Number WO 2005/020968 A3

(51) International Patent Classification⁷: A61P 29/02, 25/20

A61K 31/55,

(21) International Application Number:

PCT/EP2004/009797

(22) International Filing Date:

2 September 2004 (02.09.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0320637.2 60/537,378 3 September 2003 (03.09.2003) GB 16 January 2004 (16.01.2004) US

(71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventor; and

(75) Inventor/Applicant (for US only): MANNING, Donald [US/US]; 16 Johnston Drive, Bloomsbury, NJ 08804 (US).

(74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

with international search report

(88) Date of publication of the international search report: 19 May 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF OXCARBAZEPINE FOR THE TREATMENT OF DIABETIC NEUROPATHIC PAIN AND THE IMPROVE-MENT OF SLEEP



(57) Abstract: The present invention provides for novel uses of the carbamazepine derivative of formula (I) and its pharmaceutically acceptable salts, in particular an improved regimen for the administration of the carbamazepine derivative of formula (I) and the pharmaceutically acceptable salts thereof for the treatment of patients suffering from pain, in particular neuropathic pain, especially diabetic neuropathic pain, and the improvement of sleep; the use of oxcarbazepine for the manufacture of a pharmaceutical composition for the treatment of pain or the manufacture of a pharmaceutical composition for the improvement of sleep in human patients suffering from chronic pain; pharmaceutical compositions comprising oxcarbazepine

as sole active ingredient for the treatment of pain or for the improvement of sleep in human patients suffering from chronic pain and to packages comprising a pharmaceutical composition comprising as sole active ingredient oxcarbazepine together with instructions for the treatment of pain or together with instructions for improvement of sleep in human patients suffering from chronic pain.